Why the study?
Takotsubo syndrome is an acute heart failure syndrome often preceded by stress, but there is currently no treatment for it.
Does calcineurin inhibition improve heart function and reduce myocardial injury in a mouse model of Takotsubo syndrome?
Does calcineurin inhibition improve heart function and reduce myocardial injury in a mouse model of Takotsubo syndrome?
Answers are grounded in this paper and cite their sources.
Calcineurin inhibition with cyclosporine or tacrolimus improves heart function and reduces myocardial injury in a mouse model of Takotsubo syndrome, suggesting a potential novel therapeutic target.
Takotsubo syndrome (TTS) is an acute heart failure syndrome that mimics the symptoms of acute myocardial infarction and is often preceded by emotional and/or physical stress. There is currently no treatment for TTS. Here we show that injection of 2.5 mg kg −1 of epinephrine (EPI) into mice recapitulates numerous features of human TTS, including increased myocardial damage and mortality in males. Gene set enrichment analysis of myocardial RNA sequencing after EPI injection revealed significant enrichment of calcineurin-dependent pro-inflammatory gene networks, which was more pronounced in male than in female mice, in agreement with observed sex discrepancies in the mouse phenotype. An increase in calcineurin activity was detected in the circulating cells of patients with TTS, suggesting a systemic nature of the syndrome. Preventive and therapeutic treatment of mice injected with EPI using calcineurin inhibitors cyclosporine and tacrolimus improved heart function and reduced myocardial injury. Our findings suggest that calcineurin inhibition could be a potential therapy for TTS.
No takes yet. Share an insight, caveat, or question.
Bruns et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: